Analyst Price Targets — AGL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:08 am | — | Wells Fargo | $141.00 | $114.85 | TheFly | Agilon Health price target raised to $141 from $72 at Wells Fargo |
| May 26, 2026 12:53 pm | Andrew Mok | Barclays | $81.00 | $88.07 | TheFly | Agilon Health upgraded to Equal Weight from Underweight at Barclays |
| May 8, 2026 10:23 am | — | Wells Fargo | $72.00 | $60.66 | TheFly | Agilon Health price target raised to $72 from $37.50 at Wells Fargo |
| May 7, 2026 8:50 am | Jack Slevin | Jefferies | $48.00 | $27.85 | TheFly | Agilon Health upgraded to Buy from Hold at Jefferies |
| May 7, 2026 8:48 am | — | Deutsche Bank | $49.00 | $27.85 | TheFly | Agilon Health upgraded to Buy from Hold at Deutsche Bank |
| April 9, 2026 12:47 pm | George Hill | Deutsche Bank | $33.00 | $19.84 | TheFly | Agilon Health price target adjusted to $33 from $2 at Deutsche Bank |
| April 8, 2026 1:02 pm | — | Evercore ISI | $16.00 | $18.47 | TheFly | Agilon Health price target adjusted to $16 at Evercore ISI after reverse split |
| October 7, 2025 10:51 am | — | Wells Fargo | $37.50 | $28.00 | TheFly | Agilon Health price target lowered to $1.50 from $5 at Wells Fargo |
| August 15, 2025 3:08 pm | Jack Slevin | Jefferies | $27.50 | $27.38 | TheFly | Agilon Health price target lowered to $1.10 from $2.40 at Jefferies |
| October 29, 2024 4:08 pm | Daniel Grosslight | Citigroup | $62.50 | $63.00 | StreetInsider | Citi Downgrades agilon health Inc (AGL) to Sell |
Latest News for AGL
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gross savings (13.6% gross savings rate), including $54 million savings in the Medicare Trust Fund, during the 2024 performance year of the ACO Realizing Equity, Access and…
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for…
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGL.
U.S. House Trading
No House trades found for AGL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.